STOCK TITAN
  1. Home
  2. Sec-filings
  3. IKT
  4. [EFFECT] Inhibikase Therapeutics, Inc. SEC Filing

[EFFECT] Inhibikase Therapeutics, Inc. SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
EFFECT
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: June 27, 2025 4:01 P.M.
Form: S-3
CIK: 0001750149
Company Name: Inhibikase Therapeutics, Inc.
File Number: 333-288213

Source: View Original Filing on SEC EDGAR

Stock IKT logo
Inhibikase Therapeutics Inc

NASDAQ:IKT

IKT Rankings

#4381 Ranked by Market Cap
N/A Ranked by Dividends

IKT Latest News

Nov 20, 2025
Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants
Nov 20, 2025
Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Nov 20, 2025
Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension
Nov 14, 2025
Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity
Aug 19, 2025
Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer

IKT Latest SEC Filings

Feb 24, 2026
[Form 4] Inhibikase Therapeutics, Inc. Insider Trading Activity
Feb 24, 2026
[Form 4] Inhibikase Therapeutics, Inc. Insider Trading Activity
Feb 24, 2026
[Form 4] Inhibikase Therapeutics, Inc. Insider Trading Activity
Feb 17, 2026
[SCHEDULE 13G/A] Inhibikase Therapeutics, Inc. Amended Passive Investment Disclosure
Feb 17, 2026
[SCHEDULE 13G/A] Inhibikase Therapeutics, Inc. Amended Passive Investment Disclosure

IKT Stock Data

236.47M
105.80M
Biotechnology
Biological Products, (no Diagnostic Substances)
Link
United States
WILMINGTON